Fate Therapeutics, Inc. (FATE)
FATE moved a median of -0.76% 30 minutes after news, and -0.81% by the close. How FATE actually reacts to news — the realized, point-in-time move the market made, measured across 287 labeled events over the last three years with zero look-ahead.
FATE’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 43% | 284 |
| 30-min | -0.76% | 39% | 284 |
| 60-min | -0.75% | 34% | 284 |
| to close | -0.81% | 41% | 283 |
| Middle 50% of FATE reactions | -2.37% to +1.08% |
|---|---|
| Median reaction (30-min) | -0.76% |
| Measured reactions | 287 |
Half of all Fate Therapeutics, Inc. news events land between -2.37% and +1.08% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How FATE reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 15 | -2.50% | 13% | -3.90% |
| Rating reiterations | 59 | -0.39% | 41% | -2.14% |
| Price-target cuts | 12 | -1.10% | 42% | -2.00% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how FATE ranks against every other measured name →
That’s how FATE usually reacts — get an email when it moves on news →Email me when FATE moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to FATE's baseline. Nothing else.
Recent FATE events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies | Press release | GlobeNewswire | -0.47% | +0.00% | |
| Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.17% | -0.85% | |
| Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences | Press release | GlobeNewswire | -0.21% | -2.95% | |
| Form 8-K FATE THERAPEUTICS INC For: Sep 25 | SEC filing · Form 8-K | SEC EDGAR | -0.43% | +3.48% | |
| Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN | Press release | GlobeNewswire | -0.85% | +0.43% | |
| Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026 | Press release | GlobeNewswire | +1.06% | +3.39% | |
| Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting | Press release | GlobeNewswire | -0.60% | -1.61% | |
| Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference | Press release | GlobeNewswire | +1.84% | -1.22% | |
| Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis | Press release | GlobeNewswire | -2.33% | -0.39% | |
| Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates | Press release | GlobeNewswire | -1.41% | -10.95% | |
| Form 10-Q FATE THERAPEUTICS INC For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.41% | -10.95% | |
| Form 8-K FATE THERAPEUTICS INC For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | -1.41% | -10.95% | |
| Form S-8 FATE THERAPEUTICS INC | SEC filing · Form S-8 | SEC EDGAR | -2.33% | -0.39% | |
| Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.19% | +1.58% | |
| Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate | Press release | GlobeNewswire | +0.34% | +4.71% | |
| Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting | Press release | GlobeNewswire | -1.02% | +2.05% | |
| Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences | Press release | GlobeNewswire | -1.33% | -3.63% | |
| Fate Therapeutics Appoints Laura Hamill to Board of Directors | Press release | GlobeNewswire | +0.00% | -3.83% | |
| Form 8-K FATE THERAPEUTICS INC For: Jun 12 | SEC filing · Form 8-K | SEC EDGAR | -1.68% | -6.40% | |
| Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting | Press release | GlobeNewswire | -2.43% | -0.45% | |
| Form 8-K FATE THERAPEUTICS INC For: Jun 04 | SEC filing · Form 8-K | SEC EDGAR | +0.47% | -7.91% | |
| Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.20% | -11.55% | |
| Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting | Press release | GlobeNewswire | -3.67% | +0.37% | |
| Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases | Press release | GlobeNewswire | +0.84% | +17.32% | |
| Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes | Press release | Canada Newswire | -4.12% | +11.18% | |
| Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates | Press release | GlobeNewswire | -2.51% | -2.51% | |
| Form 10-Q FATE THERAPEUTICS INC For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -2.51% | -2.51% | |
| Form 8-K FATE THERAPEUTICS INC For: May 13 | SEC filing · Form 8-K | SEC EDGAR | -2.51% | -2.51% | |
| Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting | Press release | GlobeNewswire | +2.54% | -7.63% | |
| Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819 | Press release | GlobeNewswire | +2.93% | +15.12% | |
| Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases | Press release | GlobeNewswire | +16.34% | +17.65% | |
| Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +16.34% | +17.65% | |
| Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting | Press release | GlobeNewswire | +2.54% | +2.46% | |
| Form ARS FATE THERAPEUTICS INC For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -1.47% | -3.68% | |
| Form DEF 14A FATE THERAPEUTICS INC For: Jun 12 | SEC filing · Form DEF | SEC EDGAR | -1.47% | -3.68% | |
| Form DEFA14A FATE THERAPEUTICS INC | SEC filing · Form DEFA14A | SEC EDGAR | -1.47% | -3.68% | |
| Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR Annu | Press release | GlobeNewswire | -0.37% | +1.48% | |
| Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences | Press release | GlobeNewswire | +0.42% | +6.72% | |
| Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.00% | -2.46% | |
| Scalable Biotech Manufacturing Unlocks a $14B Market | Press release | Canada Newswire | -0.41% | -4.10% | |
| The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t Noticed | Press release | GlobeNewswire | -0.46% | -3.20% | |
| Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.77% | -2.13% | |
| Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them | Press release | PR Newswire | +2.21% | +0.73% | |
| Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference | Press release | GlobeNewswire | -1.07% | +3.57% | |
| Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates | Press release | GlobeNewswire | -2.14% | +6.85% | |
| Form 10-K FATE THERAPEUTICS INC For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -2.14% | +6.85% | |
| Form 8-K FATE THERAPEUTICS INC For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | -2.14% | +6.85% | |
| Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -3.36% | -3.36% | |
| Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +2.00% | +1.00% | |
| Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs | Press release | GlobeNewswire | +1.39% | -0.93% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the FATE section they belong to.
Where else FATE is measured.
FATE earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Accuray Incorporated (ARAY) | 288 | 0.00% | 51% |
| Chemed Corp (CHE) | 288 | +0.02% | 53% |
| RenovaCare, Inc. (RCAR) | 286 | 0.00% | 41% |
| Cellectis S.A. - American Depositary Shares (CLLS) | 285 | -0.01% | 37% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Fate Therapeutics, Inc.'s median reaction calculated?
Every labeled FATE news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 287 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 39% of FATE's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does FATE's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.